Reshaping the HIV treatment and prevention landscape
Dovato: Best-in-class two-drug regimen
Switch share growing strongly in US and EU
60%
50%
40%
30%
20%
10%
gsk
>£1bn by 2022 and further potential beyond
Integrase inhibitors gold standard with proven
high bar to resistance and tolerability
-
Only 2DR to deliver durable efficacy and high
barrier to resistance in naïve and switch
One in two people on treatment globally on DTG
regimens with 8 superiority studies
Patent protection to April 2028 US/July 2029 EU*
0%
Jun
Sep
2019
2019
Sep
2019
Mar
2020
Jun
2020
Sep
2020
Dec
2020
Mar
2021
May
2021
US Competitor
EU Competitor
EU Dovato
US Dovato
Source: IQVIA (R4W) and ActOne (R3M)
*Dovato is protected by composition of matter patent protections until 2028 in US / 2029 in EU,
and assuming paediatric exclusivity granted.
DTG dolutegravir.
74View entire presentation